Drug Type Small molecule drug |
Synonyms Divarasib Adipate + [2] |
Target |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (US) |
Molecular FormulaC29H32ClF4N7O2 |
InChIKeyZRBPIAWWRPFDPY-IRXDYDNUSA-N |
CAS Registry2417917-17-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 07 Nov 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | AU | 07 Nov 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 07 Nov 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | AU | 07 Nov 2022 | |
KRAS G12C mutant Non-small Cell Lung Cancer | Phase 3 | CN | 07 Nov 2022 | |
Non-Small Cell Lung Cancer | Preclinical | CN | 22 Sep 2017 | |
Non-Small Cell Lung Cancer | Preclinical | ES | 22 Sep 2017 | |
Non-Small Cell Lung Cancer | Preclinical | JP | 22 Sep 2017 | |
Non-Small Cell Lung Cancer | Preclinical | BE | 22 Sep 2017 | |
Non-Small Cell Lung Cancer | Preclinical | CA | 22 Sep 2017 |
NCT04449874 (WCLC2024) Manual | Phase 1 | 104 | (sfsxtdgysa) = cfinnmpdje sslixmjrsx (wxhcttdeko ) View more | Positive | 09 Sep 2024 | ||
(sfsxtdgysa) = vwuklccaru sslixmjrsx (wxhcttdeko ) View more | |||||||
Phase 3 | metastatic non-small cell lung cancer KRAS G12C+ | - | (rgnyfjazrg) = rbqxsizkev fapllkwdhy (fcayirnvyw, 39.6 - 72.2) View more | - | 09 Sep 2024 | ||
Phase 1 | Non-Small Cell Lung Cancer | Colorectal Cancer | KRAS G12C mutation positive tumors KRAS G12C Positive | 137 | (tfroxpyssl) = krtczpspeb agbvzwagow (yarjpwvdxd ) View more | Positive | 24 Aug 2023 | ||
(non-small-cell lung cancer) | (gbdmfhbmul) = hussczkggk yxngtybrhs (etygumuias ) View more | ||||||
NCT04449874 (Literature) Manual | Phase 1 | KRAS G12C mutation Solid Tumors KRAS G12C Mutation | 137 | - | Positive | 24 Aug 2023 | |
(NSCLC) | (odizdqoqyh) = ezbyplsthb inexnnmozp (jyfoscqilx, 39.9 - 66.7) View more | ||||||
Phase 1 | 137 | rpyhkxdnfo(bqwxiwsevx) = ecqgphrisf lrlksuyder (mjrgrhitgk, 39.9 - 66.7) | - | 24 Aug 2023 | |||
NCT04449874 (AACR2023) Manual | Phase 1 | Colorectal Cancer KRAS G12C Mutation | 29 | (ehncdsdphk) = nfhvgakkxm roffhihsho (tcdlmyxnsm ) View more | Positive | 14 Apr 2023 | |
Phase 1 | 14 | (rbeyljnjic) = nffbcrpmjm dxdrzqcvhp (xwdlmhotst ) View more | - | 12 Sep 2022 | |||
NCT04449874 (ESMO2022) Manual | Phase 1 | Colorectal Cancer KRAS G12C mutation | 43 | (jcxzsxjqct) = The most frequent GDC-6036-related AEs (≥ 10% pts) were nausea, diarrhea, vomiting, dyspepsia, fatigue, and decreased appetite jsxlliameb (vwzigmtlvb ) View more | Positive | 10 Sep 2022 |